Differences in

Acute myeloid leukemia Anthracycline Daunorubicin Idarubicin Mitoxantrone Personalized medicine ex-vivo test

Journal

Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512

Informations de publication

Date de publication:
2019
Historique:
received: 10 10 2018
accepted: 12 01 2019
entrez: 13 3 2019
pubmed: 13 3 2019
medline: 13 3 2019
Statut: epublish

Résumé

Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates. Using an Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC A third of the patients could benefit from the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed.

Sections du résumé

BACKGROUND BACKGROUND
Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates.
MATERIALS AND METHODS METHODS
Using an
RESULTS RESULTS
Similar dose-respond graphs were generated for the three anthracyclines, with a slight decrease in EC
DISCUSSION CONCLUSIONS
A third of the patients could benefit from the use of this test in the first line induction therapy selection, although it should be confirmed in a clinical trial specifically designed.

Identifiants

pubmed: 30858954
doi: 10.4084/MJHID.2019.016
pii: mjhid-11-1-e2019016
pmc: PMC6402555
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e2019016

Déclaration de conflit d'intérêts

Competing interests: The authors have declared that no competing interests exist.

Références

Leukemia. 1999 Jun;13(6):843-9
pubmed: 10360370
Eur J Haematol. 2001 Mar;66(3):160-7
pubmed: 11350484
Vnitr Lek. 2001 Sep;47 Suppl 1:48-56
pubmed: 11693063
Leukemia. 2001 Dec;15(12):1892-7
pubmed: 11753610
Blood. 2002 Oct 1;100(7):2292-302
pubmed: 12239137
Blood. 2004 Jan 15;103(2):479-85
pubmed: 14512295
J Clin Oncol. 2004 Sep 1;22(17):3631-8
pubmed: 15289488
Br J Haematol. 2005 Mar;128(6):783-91
pubmed: 15755281
J Clin Oncol. 1992 Jul;10(7):1103-11
pubmed: 1607916
Blood Rev. 2006 Nov;20(6):333-42
pubmed: 16920238
Blood. 1992 Jan 15;79(2):313-9
pubmed: 1730080
Blood. 2007 Jun 15;109(12):5129-35
pubmed: 17341661
J Clin Pharmacol. 2007 Aug;47(8):1014-21
pubmed: 17660484
Korean J Lab Med. 2007 Apr;27(2):89-95
pubmed: 18094557
Eur J Cancer. 1991;27(6):750-5
pubmed: 1829918
J Clin Oncol. 2009 Nov 10;27(32):5397-403
pubmed: 19826132
J Clin Oncol. 2010 Feb 10;28(5):808-14
pubmed: 20048183
Int J Hematol. 2010 Mar;91(2):276-83
pubmed: 20054669
Blood. 1991 Apr 15;77(8):1666-74
pubmed: 2015395
Blood. 2011 Feb 24;117(8):2358-65
pubmed: 20693429
Exp Hematol. 2011 Jul;39(7):741-50
pubmed: 21530609
Expert Rev Hematol. 2011 Jun;4(3):271-83
pubmed: 21668393
Haematol Blood Transfus. 1990;33:261-6
pubmed: 2182419
Blood. 2011 Oct 6;118(14):3832-41
pubmed: 21828126
Front Pharmacol. 2013 Mar 14;4:28
pubmed: 23504227
Blood. 2013 Jul 4;122(1):37-43
pubmed: 23704089
Cancer Discov. 2013 Dec;3(12):1416-29
pubmed: 24056683
Mol Cancer Ther. 2013 Dec;12(12):2940-9
pubmed: 24092807
Leukemia. 2014 Feb;28(2):440-3
pubmed: 24166215
CPT Pharmacometrics Syst Pharmacol. 2014 Jan 02;3:e88
pubmed: 24384783
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):305-18
pubmed: 24468131
Blood. 2014 May 22;123(21):3239-46
pubmed: 24687088
Curr Hematol Malig Rep. 2015 Jun;10(2):96-103
pubmed: 25921386
Cochrane Database Syst Rev. 2015 Jun 03;(6):CD010432
pubmed: 26037486
Bone Marrow Transplant. 1989 Dec;4 Suppl 3:45-6
pubmed: 2697400
Leuk Lymphoma. 1990;1(3-4):221-5
pubmed: 27463989
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2017 Aug 20;35(24):2754-2763
pubmed: 28632487
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957
pubmed: 28687581
Semin Oncol. 1989 Feb;16(1 Suppl 2):10-5
pubmed: 2928805
Leuk Res. 2018 May;68:51-56
pubmed: 29544132
Ann Hematol. 2018 Jul;97(7):1115-1153
pubmed: 29680875
Leuk Res. 2019 Jan;76:1-10
pubmed: 30468991
Blood. 1982 Aug;60(2):454-62
pubmed: 6953986
Pharmacol Rev. 1995 Jun;47(2):331-85
pubmed: 7568331
Ann Hematol. 1994 Jul;69(1):11-5
pubmed: 8061102
Leukemia. 1996 Mar;10(3):389-95
pubmed: 8642852
Med Oncol. 1998 Sep;15(3):183-90
pubmed: 9819795

Auteurs

Juan Eduardo Megías-Vericat (JE)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.

David Martínez-Cuadrón (D)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Joaquín Martínez López (JM)

Hospital Universitario 12 de Octubre, UCM, CNIO, CIBERONC, Madrid, Spain.

Juan Miguel Bergua (JM)

Hospital San Pedro de Alcántara, Cáceres, Spain.

Mar Tormo (M)

Hospital Clínico Universitario, Valencia, Spain.

Josefina Serrano (J)

Hospital Universitario Reina Sofía, Córdoba, Spain.

Ataulfo González (A)

Hospital Universitario Clínico San Carlos, Madrid, Spain.

Jaime Pérez de Oteyza (JP)

Hospital de Madrid Norte Sanchinarro, Madrid, Spain.

Susana Vives (S)

ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Belén Vidriales (B)

Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.

Pilar Herrera (P)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Juan Antonio Vera (JA)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Aurelio López Martínez (AL)

Hospital Arnau de Vilanova, Valencia, Spain.

Adolfo de la Fuente (A)

MD Anderson Cancer Center, Madrid, Spain.

Ma Lourdes Amador (ML)

Hospital de Montecelo, Pontevedra, Spain.

José-Ángel Hernández-Rivas (JÁ)

Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain.

Ma Ángeles Fernández (MÁ)

Hospital Xeral Cies, Vigo, Spain.

Carlos Javier Cerveró (CJ)

Hospital Virgen de la Luz, Cuenca, Spain.

Daniel Morillo (D)

Fundación Jiménez Díaz, Madrid, Spain.

Pilar Hernández Campo (PH)

Vivia Biotech, Tres Cantos, Madrid, Spain.

Julián Gorrochategui (J)

Vivia Biotech, Tres Cantos, Madrid, Spain.

Daniel Primo (D)

Vivia Biotech, Tres Cantos, Madrid, Spain.

José Luis Rojas (JL)

Vivia Biotech, Tres Cantos, Madrid, Spain.

Margarita Guenova (M)

Specialized Hospital for Active Treatment of Hematological Diseases, Sofía, Bulgaria.

Joan Ballesteros (J)

Vivia Biotech, Tres Cantos, Madrid, Spain.

Miguel Sanz (M)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Pau Montesinos (P)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Classifications MeSH